What FDA's adverse event reports on compounded GLP-1s actually tell patients

The FDA's MedWatch adverse event reporting system is voluntary for most reporters. Patients, clinicians, and pharmacists can submit reports when they believe a product may have contributed to a health event. The FDA also receives reports from manufacturers.

For this specific category of drugs, there is an important legal distinction: state-licensed pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act are not legally required to submit adverse event reports to the FDA. Only 503B outsourcing facilities — a smaller, FDA-registered category of compounding operations — have mandatory reporting obligations.

This means the 605 and 545 figures are almost certainly undercounts. As the FDA notes on the page where these figures appear: "federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported."

Undercounting cuts both ways: it means the actual number of adverse events is probably higher, but it also means the figures cannot be compared directly to adverse event counts for FDA-approved drugs, which have different reporting requirements and market volumes.

The FDA has analyzed its adverse event reports and identified four specific categories of concern for compounded GLP-1 drugs. Understanding each separately is more useful than treating the total count as a single risk signal. The agency formalized several related restrictions in its April 2026 compounding rules update and a separate warning letter to ProRx.

1. Dosing errors. This is the most documented category. The FDA received multiple reports of adverse events, some requiring hospitalization, related to patients measuring and self-administering incorrect doses of compounded semaglutide.

The root cause is structural: compounded semaglutide is dispensed in multi-dose vials at varying concentrations, requiring patients to draw up and measure their own doses — a process that FDA-approved GLP-1 injections (pre-filled pens with preset doses) don't require. Patients unfamiliar with syringes and with converting between milligrams, milliliters, and "units" have administered 5 to 20 times their intended dose in documented cases.

Clinicians have also contributed to the errors. The FDA documented cases in which providers prescribed doses using incorrect unit conversions, resulting in patients receiving 5 to 10 times the intended dose. In one documented case, a provider intended to prescribe 0.25 mg but prescribed 25 units, delivering five times the intended amount.

Adverse events from dosing errors in these documented cases included nausea, vomiting, abdominal pain, fainting, headache, dehydration, acute pancreatitis, and gallstones.

2. Improper storage during shipping. GLP-1 drugs require refrigeration. The FDA has received complaints that certain compounded GLP-1 products arrived warm or with inadequate ice packs. Improper storage can degrade the drug's quality and concentration.

3. Fraudulent and counterfeit products. The FDA documented cases of fraudulent compounded semaglutide and tirzepatide bearing labels identifying pharmacies that either do not exist or did not actually compound the product. One adverse event was associated with a product labeled with a licensed pharmacy that did not make it.

4. Unapproved salt forms. The FDA is aware that some compounders use semaglutide sodium or semaglutide acetate — salt forms of the drug that are chemically different from the base form used in Ozempic and Wegovy. The FDA has no information on whether these salts have the same pharmacological properties as the approved form and is not aware of any lawful basis for using them in compounding.

The 605 adverse event figure is not a count of confirmed hospitalizations. It is not a count of serious outcomes. Many of the reported adverse events are consistent with what the FDA-approved versions of these drugs also produce in some patients — nausea, gastrointestinal discomfort, and other known side effects.

This doesn't mean the figure is meaningless. It reflects a real safety signal, particularly around dosing errors, and the FDA has acted on it: issuing warnings, establishing import alerts for API from non-compliant manufacturers, and taking enforcement action against companies distributing fraudulent products.

What the figure tells a patient, specifically, is: the risks of compounded GLP-1s are not random or unpredictable. They cluster around specific failure points — dosing confusion, storage gaps, source verification, and formulation differences — that a patient and their prescriber can actively address.

• The true incidence of adverse events with compounded GLP-1s, because 503A pharmacy reporting is voluntary and incomplete

• Whether the adverse event profile of compounded versions differs meaningfully from FDA-approved versions after controlling for dosing errors and formulation differences

• The safety and pharmacological equivalence of salt forms of semaglutide used by some compounders

• How the FDA's tightening enforcement posture will affect the quality and availability of compounded GLP-1s going forward

• Is my compounded GLP-1 dispensed by a 503A or 503B pharmacy? What are the quality oversight differences between the two?

• My medication comes in a multi-dose vial. Can you walk me through exactly how to measure my dose — including which syringe to use and what measurement unit to follow?

• Does my compounded semaglutide contain the base form of the drug, or a salt form? How does that affect what I'm getting?

• How do I verify that the product I received came from the pharmacy named on the label?

• If something seems wrong — wrong color, temperature, or effect — what should I do?

The FDA encourages patients and clinicians to report adverse events and quality problems through the MedWatch Adverse Event Reporting program (accessdata.fda.gov/scripts/medwatch). You can also contact FDA's CDER Division of Drug Information at druginfo@fda.hhs.gov or 855-543-3784.

If you receive a product that arrived warm, looks unusual, or bears a label you're uncertain about, do not use it until you've spoken with your prescriber or pharmacist.

The FDA's adverse event figures on compounded GLP-1s are a safety signal worth taking seriously — not as a reason to panic or to assume that compounded GLP-1s are uniformly dangerous, but as an accurate description of where the documented risks live.

Dosing errors are preventable with clear instructions and the right syringe. Storage failures are avoidable with proper shipping verification. Counterfeit risks are reduced by using state-licensed pharmacies with verified physical addresses. Salt form concerns are addressable by asking your pharmacy what form of the drug they use.

None of this means compounded GLP-1s are safe by default. They are not FDA-approved, which means no FDA review of safety, effectiveness, or quality before they reach you. But understanding the specific, documented failure points is more useful than a headline count that tells you nothing about which risks apply to your situation. For a side-by-side comparison of formulations, see branded vs. compounded GLP-1s, and our checklist on what to ask before choosing a peptide clinic.

If you have questions about your medication's source, formulation, or dosing, take them to your prescriber or pharmacist before your next dose.